Quick Answer
Cabaletta Bio, Inc. reported R&D Expense of $142.67 million for fiscal year 2025.
Cabaletta Bio, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $142.67M | +46.8% |
| 2024 | $97.20M | +75.4% |
| 2023 | $55.42M | +41.0% |
| 2022 | $39.30M | +20.9% |
| 2021 | $32.49M | +52.0% |
| 2020 | $21.38M | +83.2% |
| 2019 | $11.67M | +161.3% |
| 2018 | $4.47M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $39.82M | +51.5% | +5.8% |
| June 30, 2025 | $37.64M | +60.7% | +29.7% |
| March 31, 2025 | $29.02M | +32.2% | +10.4% |
| September 30, 2024 | $26.29M | +90.7% | +12.2% |
| June 30, 2024 | $23.43M | +98.6% | +6.7% |
| March 31, 2024 | $21.95M | +76.6% | +59.2% |
| September 30, 2023 | $13.79M | +67.8% | +16.9% |
| June 30, 2023 | $11.80M | +24.0% | -5.1% |
- Cabaletta Bio, Inc. showed an increase of +46.8% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Cabaletta Bio, Inc.’s r&d expense has grown by 3094.0% (from $4.47 million to $142.67 million).
- The most recent figure is from Cabaletta Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: